You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology

What do we mean by disease control in AD?

Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.

Eric Simpson
MD
Eric Simpson

Learning objectives

  • Sometimes patients and physicians have differing goals in treating atopic dermatitis. Patients tend to focus on symptoms like itching, while physicians concentrate on measurable clinical signs
  • Discusses the Atopic Dermatitis Control Tool (ADCT), a new, validated six-question tool that measures the complex domain of eczema control, helping physicians understand and document patient experiences better.
Tags
symposium
MAT-US-2407083 v1.0-P Exp Date: 08/14/2026

About this expert

Dermatology

Eric Simpson

MD

Professor of Dermatology, School of Medicine, Oregon Health & Science University, Portland, US

See author’s profile
Eric Simpson

Related resources

Chronic Spontaneous Urticaria: Disease Overview
Dermatology
interactivity

Chronic Spontaneous Urticaria: Disease Overview

Effect of Type 2 Inflammation on Skin Barrier Function in AD​
Dermatology
interactivity

Effect of Type 2 Inflammation on Skin Barrier Function in AD​

Prurigo Nodularis (PN) Case Studies
Dermatology
interactivity

Prurigo Nodularis (PN) Case Studies

Type 2 Inflammation and Neuronal Sensitization in AD and PN
Dermatology
interactivity

Type 2 Inflammation and Neuronal Sensitization in AD and PN

ADVENT On Air | Clinical Perspective on Pediatric Patients With Atopic Dermatitis
Dermatology
audio

ADVENT On Air | Clinical Perspective on Pediatric Patients With Atopic Dermatitis

ADVENT On Air | Defining AD in Pediatric Patients
Dermatology
audio

ADVENT On Air | Defining AD in Pediatric Patients

ADVENT On Air | Getting to the Diagnosis of AD in Pediatric Patients
Dermatology
audio

ADVENT On Air | Getting to the Diagnosis of AD in Pediatric Patients

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case
Dermatology
interactivity

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case

Type 2 Inflammation and Infections
Type 2 Inflammation
slide presentation

Type 2 Inflammation and Infections

AD Static Infographic
Dermatology
Infographic

AD Static Infographic

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics
Dermatology
interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

Chronic Spontaneous Urticaria (CSU): Disease Overview
Dermatology
Infographic

Chronic Spontaneous Urticaria (CSU): Disease Overview

Learn more about how dysregulated type 2 inflammation contributes to polymorphous lesions and dermal epidermal splitting in bullous pemphigoid
Dermatology
Infographic

Bullous Pemphigoid (BP) Pathophysiology Infographic

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Is Pediatric AD Linked to Other Allergic Diseases?
Dermatology
expert video

Is Pediatric AD Linked to Other Allergic Diseases?

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults
Dermatology
expert video

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention
Dermatology
expert video

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria
Dermatology
expert video

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria

Skin Dyspigmentation In Prurigo Nodularis (PN)
Dermatology
interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

Long-term Impacts of AD and the Potential Benefit of Early Intervention
Dermatology
expert video

Long-term Impacts of AD and the Potential Benefit of Early Intervention

Practical Considerations in Older Patients with AD
Dermatology
expert video

Practical Considerations in Older Patients with AD

Differential Diagnosis and Disease Onset in Older Adult Patients With AD
Dermatology
expert video

Differential Diagnosis and Disease Onset in Older Adult Patients With AD

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion
Dermatology
expert video

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

The Benefits of Early Intervention in AD: More Than Skin Deep
Dermatology
expert video

The Benefits of Early Intervention in AD: More Than Skin Deep

The Cumulative Disease Burden of AD in Adult Patients
Dermatology
expert video

The Cumulative Disease Burden of AD in Adult Patients

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD
Dermatology
expert video

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

Barrier Disruption in Atopic Dermatitis and Food Allergy
Type 2 Inflammation
expert video

Barrier Disruption in Atopic Dermatitis and Food Allergy

Type 2 Inflammation in Atopic Dermatitis and Food Allergy
Type 2 Inflammation
expert video

Type 2 Inflammation in Atopic Dermatitis and Food Allergy

Prurigo Nodularis: The Patient Journey
Dermatology
videoanimation

Prurigo Nodularis: The Patient Journey

AD, PN, and CSU: Distinct, Pruritic Diseases
Dermatology
expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

Assessment of Atopic Dermatitis Burden in Children and Adolescents
Dermatology
expert video

Assessment of Atopic Dermatitis Burden in Children and Adolescents

Clinical Assessment of Prurigo Nodularis
Dermatology
expert video

Clinical Assessment of Prurigo Nodularis

Comorbidities in Children and Adolescents with Atopic Dermatitis
Dermatology
expert video

Comorbidities in Children and Adolescents with Atopic Dermatitis

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU
Dermatology
expert video

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU

A Common Link: The Role of Type 2 Inflammation in the Clinical Presentation of AD, PN, and CSU
Dermatology
expert video

A Common Link: The Role of Type 2 Inflammation in the Clinical Presentation of AD, PN, and CSU

An Overview of Prurigo Nodularis
Dermatology
expert video

An Overview of Prurigo Nodularis

Atopic Dermatitis as a Risk Factor for Food Allergy
Type 2 Inflammation
expert video

Atopic Dermatitis as a Risk Factor for Food Allergy

Disease-Specific Aspects of Itch in AD, PN, and CSU
Dermatology
expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

EAACI 2022 | Unmet Needs in the Diagnosis and Management of Chronic Urticaria
Dermatology
expert video

EAACI 2022 | Unmet Needs in the Diagnosis and Management of Chronic Urticaria

Itch in AD, PN, and CSU: Contributions of Type 2 Inflammation
Dermatology
expert video

Itch in AD, PN, and CSU: Contributions of Type 2 Inflammation

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU
Dermatology
expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

The Journey to Diagnosis: Considerations For AD, PN, and CSU
Dermatology
expert video

The Journey to Diagnosis: Considerations For AD, PN, and CSU

Pathophysiology of Prurigo Nodularis
Dermatology
expert video

Pathophysiology of Prurigo Nodularis

What is the disease burden of atopic dermatitis on children and their families
Dermatology
expert video

What is the disease burden of atopic dermatitis on children and their families

The Burden of Disease in Atopic Dermatitis
Dermatology
expert video

The Burden of Disease in Atopic Dermatitis

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU
Dermatology
expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion
Dermatology
expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

The Burden of Chronic Spontaneous Urticaria
Dermatology
videoanimation

The Burden of Chronic Spontaneous Urticaria

Type 2 Inflammation and Chronic Pruritus in AD and PN
Dermatology
expert video

Type 2 Inflammation and Chronic Pruritus in AD and PN

Type 2 Inflammation and Its Role in Associated Dermatologic Diseases: A Two-Part Series
Type 2 Inflammation
expert video

Type 2 Inflammation and Its Role in Associated Dermatologic Diseases: A Two-Part Series

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region